Gossamer Bio, Inc. (GOSS)
GOSSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$10.60
+0.7850 (+8.00%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $65.11m
- P/E
- –
- EPS, last 4 quarters
- $-65.60
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.29 to $309.60
- Average volume
- 234.0k
- Previous close
- $9.82
Analysts
3 coveringHold2 buy, 1 hold, 0 sell
Targets a year out average $110.00, +937.7% from here
Earnings
next estimate $-5.55Next report Nov 11, 2026
Sep 2025
-10.5%
Dec 2025
-5.0%
Mar 2026
-17.6%
Jun 2026
-100.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $13.29m | $13.80m | $16.95m | $9.24m |
| Gross profit | $13.29m | $13.80m | $16.95m | $9.24m |
| Operating income | -$49.11m | -$46.04m | -$44.87m | -$26.07m |
| Net income | -$48.22m | -$47.24m | -$46.66m | $16.90m |
Last four quarters: revenue $53.29m, margin -235.0%, free cash flow –
News
8 latest- TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesZacks · 14 hours ago
- Gossamer Bio Stockholders Approve Share Issuance Proposal Under Securities Purchase Agreement Dated August 20, 2026Fintel · Oct 28, 2026
- Gossamer Bio Consensus Price Target Increased by 4,500% to $135.13Fintel · Sep 15, 2026
- Gossamer Secures Up To $250M Financing To Advance Seralutinib Toward FDA Approval RTTNews · Aug 21, 2026
- Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue EstimatesZacks · Aug 13, 2026
- Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 13, 2026
- Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 12, 2026
- Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks · Jul 30, 2026
The company
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- gossamerbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.